Erkelenz

Germany

3 total trials

Filter these 3 trials by phase, condition, sponsor and more.

Open in Search →

Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment

2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk … Ended recruitment

2024-515769-32-00 5 2019-07-02 HR+/HER2- early breast cancer
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended

2023-508472-11-00 5 2018-06-13 Patients with early breast cancer

Showing 1–3 of 3 trials